Digital biomarkers market: $8.58 billion by 2029, driven by digital health

The global pharmaceutical industry is undergoing a transformation with an increasing focus on drug development using digital biomarkers, revolutionising healthcare and pharmaceutical research. Digital biomarkers, which monitor physiological and behavioural parameters through technology, offer benefits such as faster drug development, targeted therapies, and reduced costs. 

The wearables and sensors sector, particularly in clinical trials, is projected to dominate the market, with estimated revenue reaching $6.9 billion by 2029. Wearables, sensors, and mobile applications play a crucial role in capturing real-time patient data, contributing to the evolution of clinical research methods. In North America, the digital biomarkers market has seen significant growth, driven by factors such as technology adoption, increased healthcare costs, and the demand for personalised care. 

The US, accounting for 93.83% of the North American market, has experienced rapid growth in the digital biomarkers sector, propelled by innovations, regulatory guidelines, and a focus on preventative and personalised medicine. Despite the promising outlook, challenges related to data privacy, healthcare disparities, and regulatory hurdles need to be addressed to unlock the full potential of digital biomarkers. 

The future of the digital biomarkers market holds immense promise, with advancements in technology and the integration of artificial intelligence and machine learning expected to enhance its potential further.

Click here to read the original news story.